← All trials
NCT04449588
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 23, 2020
- Primary completion
- Aug 7, 2021
- Completion date
- Aug 7, 2022
- First posted
- Jun 29, 2020
- Last posted
- Jul 27, 2020
- Enrollment
- 368
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Staidson (Beijing) Biopharmaceuticals Co., LtdLead sponsor
- Beijing Defengrui Biotechnology Co. LtdCollaborator
- Southwest Hospital of ChongqingOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.